Cleveland Clinic 27th Annual Diabetes Therapeutics, Technology and Surgery
For over a quarter century, Cleveland Clinic has been at the forefront of continuing education regarding the treatment and management of diabetes. Its world class faculty has designed the 27th Annual Diabetes Therapeutics, Technology and Surgery to provide up-to-date reviews of strategies and research relevant to this disease and its complications. The goal of this activity is to increase practitioners’ competence and clinical performance in the management of type 1 and type 2 diabetes. A greater understanding of the disease and available treatment options will lead to better patient outcomes. Worth 8.5 AMA PRA Category I Credits™, this enduring material is designed for primary care physicians, endocrinologists, diabetes educators, nurses, nurse practitioners, physician assistants and dietitians, with NO POST TEST. Additionally, physicians can earn up to 8.5 ABIM MOC points for this activity.
Cost: $175.00Add to cart
Key Features
Analyzing the Latest Strategies and Complications for Types 1 and 2 Diabetes. 8.5 AMA PRA Category I Credits™ and ABIM MOC.
Topics Covered
Therapeutic management options for both Type 1 and Type 2 diabetes, hypoglycemia, diabetic cardiomyopathy, medical vs. surgical management of obesity, hypertension and lipid guidelines, GLP1 receptor agonists, SGLT-2 inhibitors, mineralocorticoid receptor antagonists, dietary carbohydrates and more.
Learning Objectives
1. Describe the efficacy and side effects of therapeutic interventions for Type 1 and Type 2 diabetes, including new insulins, closed-loop insulin pumps, smart pens, and islet and pancreas transplants.
2. Describe the new roles for SGLT-2 inhibitors, GLP-1 receptor agonists and mineralocorticoid receptor antagonists to preserve renal and cardiac function.
3. Critically appraise the use of oral agents in the hospital.
4. Describe the medical vs. surgical management of diabetes and obesity.
5. Describe goals and management strategies for treating hypertension in patients with diabetes.
6. Describe the new therapeutic options for managing hypoglycemia in patients with diabetes.
7. Summarize the pathophysiologic impact of diabetic cardiomyopathy.
8. Identify new recommendations in the revised ADA/EASD guidelines for managing hypertension and hyperlipidemia.
9. Define the treatment strategies for diabetic eye disease.
10. Recognize new therapies for neuropathy, nephropathy and vascular disease.
11. Describe new medications to prevent Type 1 diabetes.
Target Audience
This activity is designed for primary care physicians, endocrinologists, diabetes educators, pharmacists, nurses, nurse practitioners, physician assistants, dietitians, and other health care professionals who care for patients with diabetes.
Additional credit info
Release Date: 7/11/23 CME Expiration: 710/25